Modification of vaccine carriers by decoration with glycans can enhance binding to and even targeting of dendritic cells (DCs), thus augmenting vaccine efficacy. To find a specific glycan-“vector” it is necessary to know glycan-binding profile of DCs. This task is not trivial; the small number of circulating blood DCs available for isolation hinders screening and therefore advancement of the profiling. It would be more convenient to employ long-term cell cultures or even primary DCs from murine blood. We therefore examined whether THP-1 (human monocyte cell line) and DC2.4 (immature murine DC-like cell line) could serve as a model for human DCs. These cells were probed with a set of glycans previously identified as binding to circulating human CD14^low/-CD16⁺CD83⁺ DCs. In addition, we tested a subpopulation of murine CD14^low/-CD80⁺СD11c⁺CD16⁺ cells reported as relating to the human CD14^low/-CD16⁺CD83⁺ cells. Manα1–3(Manα1–6)Manβ1–4GlcNAcβ1–4GlcNAcβ bound to both the cell lines and the murine CD14^low/-CD80⁺СD11c⁺CD16⁺ cells. Primary cells, but not the cell cultures, were capable of binding GalNAcα1–3Galβ (A_di), the most potent ligand for binding to human circulating DCs. In conclusion, not one of the studied cell lines proved an adequate model for DCs processes involving lectin binding. Although the glycan-binding profile of BYRB-Rb (8.17)1Iem mouse DCs could prove useful for assessing human DCs, important glycan interactions were missing, a situation which was aggravated when employing cells from the BALB/c strain. Accordingly, one must treat results from murine work with caution when seeking vaccine targeting of human DCs, and certainly should avoid cell lines such as THP-1 and DC2.4 cells.

中文翻译：

---

DC样细胞的糖结合曲线

通过用聚糖修饰修饰疫苗载体可以增强与树突状细胞（DC）的结合甚至靶向，从而增强疫苗效力。为了找到特定的聚糖“载体”，有必要知道DC的聚糖结合概况。这个任务并不简单。可用于隔离的少量循环血DC阻碍了筛查，因此阻碍了分析的发展。使用长期的细胞培养甚至鼠血中的原代DC会更方便。因此，我们检查了THP-1（人类单核细胞系）和DC2.4（未成熟鼠类DC样细胞系）是否可以作为人类DC的模型。这些细胞用一组聚糖进行了探测，这些聚糖先前已确定与循环中的人CD14 ^{low /} -CD16 ⁺ CD83 ⁺DC。此外，我们测试鼠CD14的亚群^{低/ -} CD80 ⁺ СD11c ⁺ CD16 ⁺细胞报告作为与人CD14^{低/ -} CD16 ⁺ CD83 ⁺细胞。Manα1-3（Manα1-6）Manβ1-4GlcNAcβ1-4GlcNAcβ结合于细胞系和小鼠CD14二者^{低/ -} CD80 ⁺ СD11c ⁺ CD16 ⁺细胞。原代细胞能够结合GalNAcα1-3Galβ（A _di），是与人类循环DC结合的最有效配体。总之，没有一个研究的细胞系证明涉及凝集素结合的DC过程的适当模型。虽然BYRB-Rb（8.17）1Iem小鼠DC的聚糖结合谱可证明对评估人DC有用，但缺少重要的聚糖相互作用，当使用BALB / c株细胞时这种情况加剧了。因此，在寻找针对人DC的疫苗时，必须谨慎对待来自鼠类工作的结果，并且当然应该避免使用THP-1和DC2.4细胞等细胞系。